PDCD1 and cancer: Numerous studies have shown that PD-1/PD-L1 inhibitor treatment is more effective in cancers characterized by a higher presence of CD8+ T cells, which can serve as predictive and therapeutic biomarkers for anti-PD-1 therapy [14, 15].